<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9B520E8D-05F2-4A18-9EDF-C1503366E9E1"><gtr:id>9B520E8D-05F2-4A18-9EDF-C1503366E9E1</gtr:id><gtr:name>Eli Lilly &amp; Company Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>College of Medical, Veterinary &amp;Life Sci</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9B520E8D-05F2-4A18-9EDF-C1503366E9E1"><gtr:id>9B520E8D-05F2-4A18-9EDF-C1503366E9E1</gtr:id><gtr:name>Eli Lilly &amp; Company Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/16E52126-0A58-4600-864A-096AB049DB75"><gtr:id>16E52126-0A58-4600-864A-096AB049DB75</gtr:id><gtr:firstName>Alison</gtr:firstName><gtr:surname>Michie</gtr:surname><gtr:orcidId>0000-0002-5404-475X</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0601099"><gtr:id>DE80B214-5F5E-459C-9723-06579EEDD290</gtr:id><gtr:title>Defining the cellular origin of chronic lymphocytic leukaemia</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0601099</gtr:grantReference><gtr:abstractText>Leukaemia is a cancer that results from a disruption in the normal development of cells within the blood. This disruption can occur when regulatory elements responsible for controlling white blood cell development malfunction. We recently discovered that a disturbance in the function of a ubiquitously expressed element protein kinase C during white blood cell development, initiates a specific type of leukaemia, chronic lymphocytic leukaemia (CLL). CLL is the most common adult blood cancer in the Western world, for which there is currently no cure. While many research groups are engaged in investigating the mechanisms that can induce CLL cell death in patients as a mechanism to remove the leukaemic cells, little is known about the origin of CLL cells. Until now it has been almost impossible to address this question, as the factors responsible for this initiating this leukaemia have remained elusive. However, our novel mouse model provides us with a unique opportunity to gain fundamental knowledge about the cellular origin of CLL, and may assist in the generation of novel treatments to cure CLL. Within our university-based research laboratory, we will perform established cellular and molecular techniques to identify which cell is responsible initiating CLL. In parallel with these experiments, we will characterise the CLL-initiating cells in CLL-patient cell samples. In this way, we will uncover important information regarding the cell of origin for CLL.</gtr:abstractText><gtr:technicalSummary>B-cell chronic lymphocytic leukaemia (CLL) is the most prevalent leukaemia in the Western world with an incidence of 3 per 100,000, for which there is currently no cure. CLL cells morphologically resemble mature small B lymphocytes with a characteristic immunophenotype (CD5+CD19hiCD23+mIgMlo), a resistance to apoptosis, with up-regulation of anti-apoptotic proteins such as Bcl-2 and Mcl-1, and cell cycle arrest at the G0/G1 phase of the cell cycle. Clinically, CLL is a heterogeneous disorder in which some patients survive over a decade with stable disease, while in others the leukaemia behaves aggressively with survival measured in months. Over the last decade, several markers of poor prognostic significance have been identified, however to date no single genetic event has been associated with the initiation of CLL. In addition, the cell of origin of CLL has not been formally identified, although it is thought to originate from a maure B cell population, due to phenotypic and gene expression profiles. In an effort to address this question, we developed a unique mouse CLL model. This was achieved by retrovirally-infecting haemopoietic stem cell (HSC)-enriched cells, derived from wild type mice, with a dominant negative protein kinase C alpha (PKCa-KR) construct and culturing the cells either in in vitro or in vivo B cell generation systems. This resulted in the spontaneous generation of B lineage cells that resemble human CLL cells both at the phenotypic and molecular level, being refractory to apoptosis - possibly due to an upregulation in Bcl-2 and Mcl-1 expression levels, and arrested in G0/G1 ex vivo (Cancer Res. 66:527). These studies indicated that subversion of PKCa activity served to initiate the development of CLL. In this application, we show preliminary data demonstrating that our mouse CLL cells can be generated from recombinase activating gene deficient mice, which exhibit a development block at an early stage of B cell development, thus establishing that CLL can be derived from either an HSC or an early B cell progenitor population. Therefore, this proposal will phenotypically identify and molecularly characterise the CLL cell of origin both in our novel CLL mouse model and importantly in samples derived from CLL patients. We will then functionally characterise the mouse and human leukaemia initiating cell, both in vitro and in vivo. Collectively, the proposed studies will provide a deeper understanding of the biology of CLL, which may in turn illuminate novel avenues for therapeutic intervention.</gtr:technicalSummary><gtr:fund><gtr:end>2010-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>363854</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Glasgow</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Infection, Immunity and Inflammation</gtr:department><gtr:description>Regulation of B cell signalling during development</gtr:description><gtr:id>1C734A39-E57C-4FB4-AA91-923447FD637D</gtr:id><gtr:impact>Award of an MRC grant: G0800167</gtr:impact><gtr:outcomeId>A7F8D9D2C9A-1</gtr:outcomeId><gtr:partnerContribution>Co-supervision of post-graduate and undergraduate students. Sharing of equipment and reagents</gtr:partnerContribution><gtr:piContribution>Assisting with experiments, troubleshooting between groups in common areas of research</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Dundee</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Dundee Cancer Centre</gtr:department><gtr:description>University of Dundee</gtr:description><gtr:id>9A6149ED-8653-445A-8971-44AE5445CD66</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>5457a488b3e0a6.86744307-1</gtr:outcomeId><gtr:partnerContribution>Discussion of molecular mechanisms of compounds and provision of compound</gtr:partnerContribution><gtr:piContribution>Providing expertise on pre-clinical modeling for novel drugs. Carrying out initial in vitro experiments on cells with a novel compound</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Eli Lilly &amp; Company Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>PKCb inhibitors</gtr:department><gtr:description>EliLilly</gtr:description><gtr:id>86C9EB0B-7084-4164-840E-C27607B95BDA</gtr:id><gtr:impact>We are drafting a paper currently</gtr:impact><gtr:outcomeId>rtkso33aNoT-1</gtr:outcomeId><gtr:partnerContribution>They have provided the drug free of charge</gtr:partnerContribution><gtr:piContribution>We have been carrying out research with one of their compounds, enzastaurin</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Open Day specifically for CLL</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>AB142C89-10FF-497D-A380-F8DDC8052773</gtr:id><gtr:impact>Gave an informal presentation to the public with an interest in CLL

None yet, except that of interest.</gtr:impact><gtr:outcomeId>cUfKkp6zXG1</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Open Day</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>632C072D-9186-4186-A3BD-85759302F54C</gtr:id><gtr:impact>Showed members of the public around our research facilities

Understanding from the public on the research we carry out</gtr:impact><gtr:outcomeId>A128C4ECC36</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008,2009,2010,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Nexxus Horizons, UK</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>05D5054D-9DEA-4F3B-8DAF-0039B0379879</gtr:id><gtr:impact>I gave a seminar about the work that we were doing in the lab

Networking</gtr:impact><gtr:outcomeId>2DC584AF5A0</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Funding letter</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>4EC1E225-8579-4D7A-AEA3-7F58A4EA9B40</gtr:id><gtr:impact>Described in laymans terms the research that I do in the lab

Create awareness of our research</gtr:impact><gtr:outcomeId>4168AC6C054</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Jordanhill</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>07AF2C35-BF3A-4DA6-AD85-EE43669EE0E2</gtr:id><gtr:impact>The talk was part of the Jordanhill School secondary school Health Week, discussing the importance of diet, impact on cancer and where therapies come from. Atleast 200 pupils were present over two 1 hour talks.

Lab visits have been arranged since this talk.</gtr:impact><gtr:outcomeId>NRGiEJ2mc3d</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Lady Tata Memorial Trust Award</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>Lady Tata Memorial Trust</gtr:fundingOrg><gtr:id>D7292F90-1A74-4EF8-B1AA-78D52E23680B</gtr:id><gtr:outcomeId>h1e88LBK6gn0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>34600</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Scottish Funding Council</gtr:department><gtr:description>University of Glasgow studentship</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Government of Scotland</gtr:fundingOrg><gtr:id>2360FA42-50E7-442B-8A68-8A9EA521C017</gtr:id><gtr:outcomeId>QoNNitdf8eK0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>485000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC/AZD Project grant</gtr:description><gtr:end>2016-02-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/K014854/1</gtr:fundingRef><gtr:id>680DDF06-95D0-4006-99DE-20C486202900</gtr:id><gtr:outcomeId>ZrdBgrE4yNn</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>102928</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>GlaxoSmithKline (GSK)</gtr:description><gtr:end>2012-11-02</gtr:end><gtr:fundingOrg>GlaxoSmithKline (GSK)</gtr:fundingOrg><gtr:id>BE0B65E5-3F1D-426B-965F-E2CC7681E00F</gtr:id><gtr:outcomeId>dVVexpsNYo6</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2011-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Leukaemia Research Project Grant</gtr:description><gtr:end>2008-08-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>F1440072-6258-4DED-8168-118C04A404B9</gtr:id><gtr:outcomeId>C9D6D98DC690</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Tenovus Scotland</gtr:description><gtr:end>2014-02-02</gtr:end><gtr:fundingOrg>Tenovus Scotland</gtr:fundingOrg><gtr:fundingRef>S12/21</gtr:fundingRef><gtr:id>0BA38C5D-C0B1-4790-92A7-80DE168EEFF3</gtr:id><gtr:outcomeId>CtLyiuTSHxf</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>53487</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>KKLF Project Grant</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>The Kay Kendall Leukaemia Fund (KKLF)</gtr:fundingOrg><gtr:id>0270D336-C380-4117-A3CE-14BFA1A50751</gtr:id><gtr:outcomeId>kVrkAt6Xy5z0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>249000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>LLR Project grant</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:fundingRef>13012</gtr:fundingRef><gtr:id>8467834E-EA3E-439A-B4B4-A0E58674795C</gtr:id><gtr:outcomeId>e1xjMVZfKGE</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>327000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Research Grant</gtr:description><gtr:end>2012-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>BED5657B-890A-4CBF-A3A7-D3B9543C2215</gtr:id><gtr:outcomeId>D18962E9FE80</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>800</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Lister Bellahouston Travelling Fellowship</gtr:description><gtr:end>2009-06-02</gtr:end><gtr:fundingOrg>Bellahouston Bequest Fund</gtr:fundingOrg><gtr:id>CEBBBED1-1997-4798-A194-1D0C4FE3AAD6</gtr:id><gtr:outcomeId>mem82tehcaN0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Cryopreserved DNA/RNA/protein/cell samples from CLL patients with linked clinical data.</gtr:description><gtr:id>4AC566D1-BB4E-4B89-B6AF-8FCB95955309</gtr:id><gtr:impact>To enable further studies to investigate the biology of CLL</gtr:impact><gtr:outcomeId>MtUfc9so4hk</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>CLL cell bank</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have developed a novel CLL mouse model which we are developing to be used as an in vivo therapeutic model</gtr:description><gtr:id>F7A6429B-1320-4FAE-B7E0-6754EFC46A49</gtr:id><gtr:impact>Publications prior to the start of this grant (2) and recognition of the model - invited for talks within University departments and conferences</gtr:impact><gtr:outcomeId>6B1EA28CAEA</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>CLL model in vivo</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>27547517-350C-4D83-9B55-E0E48180C163</gtr:id><gtr:title>Nfix expression critically modulates early B lymphopoiesis and myelopoiesis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94c5c685d3379f0218b3b5a10b780fad"><gtr:id>94c5c685d3379f0218b3b5a10b780fad</gtr:id><gtr:otherNames>O'Connor C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5675e0f465511</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BBEF27F7-66C2-42E2-9B0B-D602B2811699</gtr:id><gtr:title>Generation of a poor prognostic chronic lymphocytic leukemia-like disease model: PKCa subversion induces up-regulation of PKC?II expression in B lymphocytes.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb288c1f5870c43259008f17fc02a375"><gtr:id>bb288c1f5870c43259008f17fc02a375</gtr:id><gtr:otherNames>Nakagawa R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>5675def13b083</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC3B60B5-C98D-417A-B4A4-3C5ECE86A47C</gtr:id><gtr:title>Death-associated protein kinase (DAPK) and signal transduction: regulation in cancer.</gtr:title><gtr:parentPublicationTitle>The FEBS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c00abc99f4ebb614625d4ede21114f9f"><gtr:id>c00abc99f4ebb614625d4ede21114f9f</gtr:id><gtr:otherNames>Michie AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1742-464X</gtr:issn><gtr:outcomeId>10E19AC4F98</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF226E57-B6A4-49A0-B912-442A926DA201</gtr:id><gtr:title>Modulation of PKC-a promotes lineage reprogramming of committed B lymphocytes.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb288c1f5870c43259008f17fc02a375"><gtr:id>bb288c1f5870c43259008f17fc02a375</gtr:id><gtr:otherNames>Nakagawa R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>pm_13063_23_22531924</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EAEFDF26-7379-4416-B0A3-5AD5E9ED9258</gtr:id><gtr:title>Murine models for chronic lymphocytic leukaemia.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c00abc99f4ebb614625d4ede21114f9f"><gtr:id>c00abc99f4ebb614625d4ede21114f9f</gtr:id><gtr:otherNames>Michie AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>711D4054E0B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3440443D-29DC-412F-BC47-D05126E452D0</gtr:id><gtr:title>Uptake of synthetic Low Density Lipoprotein by leukemic stem cells--a potential stem cell targeted drug delivery strategy.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b945bc40566ba0985ba53b09b54ead7"><gtr:id>9b945bc40566ba0985ba53b09b54ead7</gtr:id><gtr:otherNames>Zhou P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn><gtr:outcomeId>SEghA1WfA97</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC8B1A2B-9966-4670-A3FE-8BCB147F4C15</gtr:id><gtr:title>Dasatinib inhibits CXCR4 signaling in chronic lymphocytic leukaemia cells and impairs migration towards CXCL12.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e8b7f9e9cb075d275852885739e2980"><gtr:id>8e8b7f9e9cb075d275852885739e2980</gtr:id><gtr:otherNames>McCaig AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13063_23_23133664</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601099</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>